Takeda, Weave Bio collaborate on AI-driven automation in drug development

Takeda has entered into a collaboration to introduce Weave Bio’s AI-native regulatory automation platform across 14 ongoing drug development programmes in various global markets. The joint effort began with AI-assisted IND submission preparation and has since expanded to HAQ and RTQ processes. The collaboration comes as global regulatory agencies clarify AI stances in drug development, focusing on safety, validation, and oversight. Credit: Gorodenkoff / Shutterstock.com. Takeda has entered a collaboration to introduce Weave Bio’s AI-native regulatory automation platform across 14 ongoing drug development programmes in various global markets. The partnership aims to integrate Weave Bio’s AI tools with Takeda’s regulatory…

Source: Pharmaceutical Technology